Hansa Biopharma: Sales support, easing funding pressure as the strategic review continues
17 juli, 09:05
17 juli, 09:05
Hansa is better positioned to support its main value drivers, engage in strategic priorities, and potentially extend the number of commercial and clinical partners over the next 6-12 months. We expect a slight positive reaction, even if the 76% quarterly sales growth was softer.
17 juli, 09:05
Hansa is better positioned to support its main value drivers, engage in strategic priorities, and potentially extend the number of commercial and clinical partners over the next 6-12 months. We expect a slight positive reaction, even if the 76% quarterly sales growth was softer.
Stockholmsbörsen
Skanska
Rapportperioden
Aktierekommendationer
Swedbank
Stockholmsbörsen
Skanska
Rapportperioden
Aktierekommendationer
Swedbank
1 DAG %
Senast
Boliden
Igår, 17:55
Många stora kursrörelser efter rapporter
OMX Stockholm 30
1 DAG %
Senast
2 546,70